Neuroone Medical Technologies annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Neuroone Medical Technologies Debt-to-Equity Ratio Growth & History (NMTC)
Neuroone Medical Technologies's debt-to-equity ratio was 0.04 for fiscal 2025.
View full Neuroone Medical Technologies company overviewNeuroone Medical Technologies annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | 0.04 | −0.28 | −88.08% |
| 2024 | 2024-09-30 | 0.32 | 0.26 | +436.30% |
| 2023 | 2023-09-30 | 0.06 | 0.03 | +137.04% |
| 2022 | 2022-09-30 | 0.02 | −0.04 | −59.79% |
| 2021 | 2021-09-30 | 0.06 | −0.67 | −91.56% |
| 2020 | 2020-09-30 | 0.73 | — | — |
Neuroone Medical Technologies quarterly debt-to-equity ratio
Q2.19
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | 0.05 | 0.01 | +28.70% |
| Q2 2026 | 2026-03-31 | 0.04 | −0.24 | −85.26% |
| Q1 2026 | 2025-12-31 | 0.04 | −0.08 | −68.13% |
| Q4 2025 | 2025-09-30 | 0.04 | −0.28 | −88.08% |
| Q3 2025 | 2025-06-30 | 0.04 | −0.06 | −62.46% |
| Q2 2025 | 2025-03-31 | 0.28 | 0.21 | +337.32% |
| Q1 2025 | 2024-12-31 | 0.12 | 0.08 | +234.40% |
| Q4 2024 | 2024-09-30 | 0.32 | 0.26 | +436.30% |
| Q3 2024 | 2024-06-30 | 0.10 | 0.02 | +24.49% |
| Q2 2024 | 2024-03-31 | 0.06 | 0.02 | +43.54% |
| Q1 2024 | 2023-12-31 | 0.03 | −0.00 | −7.52% |
| Q4 2023 | 2023-09-30 | 0.06 | 0.03 | +137.04% |
| Q3 2023 | 2023-06-30 | 0.08 | 0.05 | +197.76% |
| Q2 2023 | 2023-03-31 | 0.04 | 0.02 | +85.27% |
| Q1 2023 | 2022-12-31 | 0.04 | 0.02 | +73.09% |
| Q4 2022 | 2022-09-30 | 0.02 | −0.04 | −59.79% |
| Q3 2022 | 2022-06-30 | 0.03 | −0.02 | −44.41% |
| Q2 2022 | 2022-03-31 | 0.02 | −0.02 | −42.18% |
| Q1 2022 | 2021-12-31 | 0.02 | −0.32 | −93.60% |
| Q4 2021 | 2021-09-30 | 0.06 | −0.67 | −91.56% |
| Q3 2021 | 2021-06-30 | 0.05 | — | — |
| Q2 2021 | 2021-03-31 | 0.04 | — | — |
| Q1 2021 | 2020-12-31 | 0.34 | — | — |
| Q4 2020 | 2020-09-30 | 0.73 | — | — |
| Q2 2019 | 2019-03-31 | 0.52 | — | — |
Neuroone Medical Technologies debt-to-equity ratio trends
Over the last five fiscal years, Neuroone Medical Technologies's debt-to-equity ratio decreased from 0.73 to 0.04, a change of −0.70. The latest reported quarter, Q3 2026, shows 0.05.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Neuroone Medical Technologies source filings ↗